Scarica l'app Stockscreener
12.67
0.55%
-0.07
Dopo l'orario di chiusura:
12.58
-0.09
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$12.74
Aprire:
$12.74
Volume 24 ore:
2.36M
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.68B
Reddito:
-
Utile/perdita netta:
$-766.97M
Rapporto P/E:
-1.654
EPS:
-7.66
Flusso di cassa netto:
$-646.43M
1 W Prestazione:
-0.08%
1M Prestazione:
+13.63%
6M Prestazione:
-6.15%
1 anno Prestazione:
-68.27%
Intervallo 1D:
$12.26
$12.87
Intervallo di 1 settimana:
$12.26
$14.01
Portata 52W:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Confronta BHVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
12.67 | 1.69B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-21 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Aug Action: Is First Merchants Corporation attractive for institutional investorsEarnings Risk Summary & Real-Time Volume Triggers - baoquankhu1.vn
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Assessing Biohaven (BHVN) Valuation After A Sharp Momentum Rebound - Yahoo Finance
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
RBC Capital Upgrades Biohaven (BHVN) - Nasdaq
BHVN Upgraded by RBC Capital: New Price Target of $22 | BHVN Sto - GuruFocus
RBC Upgrades Biohaven to Outperform From Sector Perform, Boosts Price Target to $22 From $9, Keeps Speculative Risk - marketscreener.com
Biohaven stock rating upgraded by RBC Capital on promising CNS data - Investing.com South Africa
(BHVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Biohaven (BHVN) Is Up 15.6% After Showcasing MoDE and TRAP Degrader Data in Autoimmune Diseases - Sahm
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly - BioSpace
Assessing Biohaven (BHVN) Valuation After Positive MoDE And TRAP Degrader Clinical Updates - Sahm
Pomerantz To Lead Biohaven Investors' FDA Approval Suit - Law360
Biohaven (NYSE:BHVN) Stock Price Up 8%Still a Buy? - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data - Intellectia AI
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know - Benzinga
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Can Biohaven Ltd. deliver alphaMarket Weekly Review & Low Risk High Reward Ideas - bollywoodhelpline.com
Biohaven Ltd. (BHVN) Investor Outlook: Navigating Opportunities with a 68% Upside Potential - DirectorsTalk Interviews
Biohaven (NYSE:BHVN) Shares Down 6.3%Here's Why - MarketBeat
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases - simplywall.st
Biohaven stock maintains Outperform rating at Baird on promising IgAN data - Investing.com
Biohaven stock maintains Outperform rating at Baird on promising IgAN data By Investing.com - Investing.com South Africa
Biohaven highlights degrader platforms in new investor presentation - TipRanks
Biohaven Ltd Announces Investor Presentation on January 12, 2026 - TradingView
Biohaven reports early patient data from protein degrader programs - StreetInsider
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PR Newswire
Aug Update: Is Biohaven Ltd stock oversold or undervaluedJuly 2025 Volume & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Biohaven Ltd. (BHVN) upgraded to buy: Here's what you should know - MSN
(BHVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jobs Data: Why Biohaven Ltd stock attracts global investorsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - moha.gov.vn
Volatility Watch: Why Biohaven Ltd stock attracts global investorsEarnings Growth Summary & Real-Time Volume Triggers - moha.gov.vn
Will Biohaven Ltd. stock continue dividend increasesQuarterly Profit Review & Verified Chart Pattern Signals - Улправда
Is Biohaven Ltd. stock overvalued by current metricsMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Biohaven Ltd. stock recover faster than peersTrade Volume Report & Daily Risk Controlled Trade Plans - ulpravda.ru
Aug Final Week: Is Biohaven Ltd. stock oversold or undervaluedQuarterly Portfolio Report & Long-Term Growth Stock Strategies - Улправда
Is Biohaven Ltd. stock oversold or undervalued2025 Buyback Activity & Low Drawdown Investment Ideas - Улправда
Biohaven (NYSE:BHVN) Shares Up 11.9%Here's Why - MarketBeat
Biohaven expects to raise $125M in stock sale - Hartford Business Journal
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven Announces $125 Million Targeted Equity Financing - TipRanks
Biohaven Ltd. Announces $125 Million Share Sale - TradingView — Track All Markets
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 96% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Biohaven Ltd. Common Shares stock is a strong analyst pick2026 world cup usa national team round of 32 star players transition play knockout prediction preview - ulpravda.ru
Morgan Stanley Lowers Price Target for Biohaven (BHVN) to $21 | - GuruFocus
Morgan Stanley Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
Stock market today: Dow Jones, S&P 500 futures slip after Christmas Day—Nvidia, Sobr Safe, Biohaven in focus - MSN
Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Biohaven (NYSE:BHVN) Trading Down 8%Here's What Happened - MarketBeat
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):